Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

380 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team.
Bakshi SS, Britto P, Capparelli E, Mofenson L, Fowler MG, Rasheed S, Schoenfeld D, Zimmer B, Frank Y, Yogev R, Jimenez E, Salgo M, Boone G, Pahwa SG. Bakshi SS, et al. Among authors: mofenson l. J Infect Dis. 1997 May;175(5):1039-50. doi: 10.1086/520351. J Infect Dis. 1997. PMID: 9129064 Clinical Trial.
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316.
Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, Dorenbaum A, Delfraissy JF, Bazin B, Mofenson L, Sullivan JL. Cunningham CK, et al. Among authors: mofenson l. J Infect Dis. 2002 Jul 15;186(2):181-8. doi: 10.1086/341300. Epub 2002 Jun 26. J Infect Dis. 2002. PMID: 12134253 Clinical Trial.
The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Mofenson LM, Korelitz J, Meyer WA 3rd, Bethel J, Rich K, Pahwa S, Moye J Jr, Nugent R, Read J. Mofenson LM, et al. J Infect Dis. 1997 May;175(5):1029-38. doi: 10.1086/516441. J Infect Dis. 1997. PMID: 9129063 Clinical Trial.
Progress in prevention of perinatal HIV-1.
Fowler MG, Mofenson L. Fowler MG, et al. Among authors: mofenson l. Acta Paediatr Suppl. 1997 Jun;421:97-103. doi: 10.1111/j.1651-2227.1997.tb18329.x. Acta Paediatr Suppl. 1997. PMID: 9240867
A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
McKinney RE Jr, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, Brouwers P, Mitchell WG, Yogev R, Wara DW, Wiznia A, Mofenson L, McNamara J, Spector SA. McKinney RE Jr, et al. Among authors: mofenson l. J Pediatr. 1998 Oct;133(4):500-8. doi: 10.1016/s0022-3476(98)70057-5. J Pediatr. 1998. PMID: 9787687 Clinical Trial.
Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
Nachman SA, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, Mofenson L, Fiscus S, Rathore M, Jimenez E, Borkowsky W, Pitt J, Smith ME, Wells B, McIntosh K. Nachman SA, et al. Among authors: mofenson l. JAMA. 2000 Jan 26;283(4):492-8. doi: 10.1001/jama.283.4.492. JAMA. 2000. PMID: 10659875 Clinical Trial.
Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team.
Lambert JS, Watts DH, Mofenson L, Stiehm ER, Harris DR, Bethel J, Whitehouse J, Jimenez E, Gandia J, Scott G, O'Sullivan MJ, Kovacs A, Stek A, Shearer WT, Hammill H, van Dyke R, Maupin R, Silio M, Fowler MG. Lambert JS, et al. Among authors: mofenson l. AIDS. 2000 Jul 7;14(10):1389-99. doi: 10.1097/00002030-200007070-00012. AIDS. 2000. PMID: 10930154 Clinical Trial.
Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.
Capparelli EV, Sullivan JL, Mofenson L, Smith E, Graham B, Britto P, Becker MI, Holland D, Connor JD, Luzuriaga K; Pediatric ACTG 356 Investigators. Capparelli EV, et al. Among authors: mofenson l. Pediatr Infect Dis J. 2001 Aug;20(8):746-51. doi: 10.1097/00006454-200108000-00006. Pediatr Infect Dis J. 2001. PMID: 11734735 Clinical Trial.
Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response.
Kovacs A, Montepiedra G, Carey V, Pahwa S, Weinberg A, Frenkel L, Capparelli E, Mofenson L, Smith E, McIntosh K, Burchett SK; Pediatric AIDS Clinical Trials Group 366 Study Team. Kovacs A, et al. Among authors: mofenson l. J Infect Dis. 2005 Jul 15;192(2):296-302. doi: 10.1086/430922. Epub 2005 Jun 14. J Infect Dis. 2005. PMID: 15962224 Clinical Trial.
Antimicrobial-specific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy.
Weinberg A, Pahwa S, Oyomopito R, Carey VJ, Zimmer B, Mofenson L, Kovacs A, Burchett SK; Pediatric AIDS Clinical Trials Group 366 Team. Weinberg A, et al. Among authors: mofenson l. Clin Infect Dis. 2004 Jul 1;39(1):107-14. doi: 10.1086/420931. Epub 2004 Jun 14. Clin Infect Dis. 2004. PMID: 15206061
380 results